Moderna (MRNA) shares surged 125% in six months: breakthrough in flu vaccine and strategy shift
Shares of biotech giant Moderna (NASDAQ: MRNA) closed Friday, June 26, with a powerful 12% surge. Over the past six months, the company's stock price has soared 125.51%, reaching levels that recently seemed unattainable.
This rapid ascent began from lows near $46 recorded in early June. However, this rally is driven not just by market euphoria but by a series of fundamental catalysts.
Unanimous FDA Support: Key Risk Eliminated
The key driver was a historic event. On June 18, the FDA's Vaccines and Related Biological Products Advisory Committee unanimously (9 out of 9 votes) supported a positive assessment of the drug mFLUSIVA (mRNA-1010) — a seasonal mRNA-based influenza vaccine for people over 50. A unanimous decision at this level in the biotech sector is extremely rare. It has virtually eliminated regulatory uncertainty ahead of the key decision date on August 5. If approved, mFLUSIVA would become the first seasonal mRNA-based influenza vaccine in the U.S., opening access to a massive market for Moderna.
Wall Street Remains Cautious but Adjusts Targets
Despite the impressive growth, analysts at major banks show cautious optimism. Piper Sandler raised its price target for MRNA to $77, and Jefferies to $53, maintaining a "hold" rating. The median analyst forecast is just $43.45 — significantly below current trading levels. Bearish sentiment prevails in the market: 75 of the latest insider transactions were sales. Analysts do not expect significant revenue from influenza vaccine sales before 2027.
Beyond Vaccines: New Strategy and Oncology
Alongside the vaccine news, Moderna reorganized its business, highlighting three key areas: vaccines, oncology, and rare diseases. This news lifted the stock by approximately 6.3%. On Science Day, June 25, the company presented an expanded development portfolio, including programs for in vivo CAR-T and T-cell engagers for treating oncological and autoimmune diseases. Additionally, plans to invest in manufacturing in Germany, including at sites that BioNTech is closing, added another 8–12% to the stock's growth. The market interpreted this as a long-term bet on increasing capacity ahead of new product launches in 2027–2028.
My View: The current rise in MRNA is a classic case of "buying on expectations." The regulatory success of mFLUSIVA is a powerful signal, but real cash flows are still far off. The main interest now lies not so much in the influenza vaccine but in the company's transformation into a multi-specialty biotech hub with a focus on oncology. If Moderna can replicate the success of mRNA in oncology, current price levels could prove to be just the beginning of a long-term trend. However, high volatility and insider caution require investors to have patience and a clear understanding of the risks.